Brii Biosciences Ltd
HKEX:2137

Watchlist Manager
Brii Biosciences Ltd Logo
Brii Biosciences Ltd
HKEX:2137
Watchlist
Price: 1.54 HKD 4.76% Market Closed
Market Cap: 1.1B HKD

EV/EBIT
Enterprise Value to EBIT

3.1
Current
2.6
Median
6.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
3.1
=
Enterprise Value
-1.2B HKD
/
EBIT
-339.5m CNY
All Countries
Close
EBIT Growth EV/EBIT to Growth
CN
Brii Biosciences Ltd
HKEX:2137
Average EV/EBIT: 41.4
3.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 064.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
NL
argenx SE
XBRU:ARGX
61.1
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
195.2
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
3
2-Years Forward
EV/EBIT
2.6
3-Years Forward
EV/EBIT
2.6